How has been the historical performance of Ishita Drugs?

Answer:The historical performance of Ishita Drugs shows a mixed trend in various financial metrics over the years. Breakdown: Ishita Drugs' net sales for the year ending March 2025 were reported at 15.00 crore, a slight decrease from 15.19 crore in March 2024, but an increase from 12.07 crore in March 2023. The total operating income mirrored this trend, with a total of 15.00 crore in March 2025 compared to 15.19 crore in the previous year. The company's total expenditure, excluding depreciation, decreased to 14.00 crore in March 2025 from 14.28 crore in March 2024. Consequently, the operating profit (PBDIT) rose to 1.34 crore in March 2025, up from 1.19 crore in March 2024. Profit before tax also increased to 1.16 crore in March 2025 from 0.99 crore in March 2024, leading to a profit after tax of 0.87 crore, compared to 0.75 crore in the previous year. The earnings per share (EPS) improved to 2.91 in March 2025 from 2.51 in March 2024. On the balance sheet, total assets grew to 16.30 crore in March 2025 from 10.81 crore in March 2024, while total liabilities also increased to 16.30 crore from 10.81 crore. The company reported a cash flow from operating activities of -3.00 crore in March 2025, a decline from 2.00 crore in March 2024, indicating challenges in cash generation despite the increase in profits. Overall, while Ishita Drugs has shown growth in sales and profitability, it faces fluctuations in cash flow and rising liabilities.